Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
Frontiers in Pharmacology · 10.04.2023 · 14
DOI: 10.3389/fphar.2023.1161891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.04.2023. Verfasst von Lena Wucherpfennig und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Chronic rhinosinusitis (CRS) usually presents with nasal congestion, rhinorrhea and anosmia impacts quality of life in cystic fibrosis (CF). Especially mucopyoceles pathognomonic for CRS in CF may cause complications such as spread of infection. Previous studies using magnetic resonance imaging (MRI) demonstrated early onset and progression of CRS from infancy to school age in patients with CF, and mid-term improvements of CRS in preschool and school-age children with CF treated with lumacaftor/ivacaftor for at least 2 months. However, long-term data on treatment effects on paranasal sinus abnomalities in preschool and school-age children with CF are lacking.
Methods
39 children with CF homozygous for F508del (mean age at baseline MRI 5.9 ± 3.0 years, range 1-12 years) underwent MRI before (MRI1) and about 7 months after starting lumacaftor/ivacaftor and then annually (median 3 follow-up MRI, range 1–4) (MRI2-4). MRI were evaluated using the previously evaluated CRS-MRI score with excellent inter-reader agreement. For intraindividual analysis ANOVA mixed-effects analysis including Geisser-Greenhouse correction and Fisher’s exact test, and for interindividual group analysis Mann-Whitney test were used.
Results
The CRS-MRI sum score at baseline was similar in children starting lumacaftor/ivacaftor in school age and children starting therapy at preschool age (34.6 ± 5.2 vs.32.9 ± 7.8, p = 0.847). Mucopyoceles were the dominant abnormality in both, especially in maxillary sinus (65% and 55%, respectively). In children starting therapy in school age the CRS-MRI sum score decreased longitudinally from MRI1 to MRI2 (−2.1 ± 3.5, p < 0.05), MRI3 (−3.0 ± 3.7, p < 0.01) and MRI4 (−3.6 ± 4.7, p < 0.01), mainly due to a decrease in the mucopyoceles subscore (−1.0 ± 1.5, p = 0.059; −1.2 ± 2.0, p < 0.05; −1.6 ± 1.8, p < 0.01; and −2.6 ± 2.8, p = 0.417, respectively). In children starting lumacaftor/ivacaftor in preschool age, the CRS-MRI sum score remained stable under therapy over all three follow-up MRI (0.6 ± 3.3, p = 0.520; 2.4 ± 7.6, p = 0.994; 2.1 ± 10.5, p > 0.999 and −0.5 ± 0.5, p = 0.740; respectively).
Conclusion
Longitudinal paranasal sinus MRI shows improvements in paranasal sinus abnormalities in children with CF starting lumacaftor/ivacaftor therapy at school age. Further, MRI detects a prevention of an increase in paranasal sinus abnormalities in children with CF starting lumacaftor/ivacaftor therapy at preschool age. Our data support the role of MRI for comprehensive non-invasive therapy and disease monitoring of paranasal sinus abnormalities in children with CF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology with Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology and Neuroradiology, Helios Dr. Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany.
- Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Förderung
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Wucherpfennig, L., Wuennemann, F., Eichinger, M., Seitz, A., Baumann, I., Stahl, M., Graeber, S. Y., Zhao, S., Chung, J., Schenk, J. P., Alrajab, A., Kauczor, H. U., Mall, M. A., Sommerburg, O., & Wielpütz, M. O. (2023). Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1161891
Vancouver
Wucherpfennig L, Wuennemann F, Eichinger M, Seitz A, Baumann I, Stahl M, et al. Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1161891
BibTeX
@article{Wucherpfennig2023,
author = {Wucherpfennig, Lena and Wuennemann, Felix and Eichinger, Monika and Seitz, Angelika and Baumann, Ingo and Stahl, Mirjam and Graeber, Simon Y and Zhao, Shengkai and Chung, Jaehi and Schenk, Jens-Peter and Alrajab, Abdulsattar and Kauczor, Hans-Ulrich and Mall, Marcus A and Sommerburg, Olaf and Wielpütz, Mark O},
title = {Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1161891}
}
EUVIMED